Skip to main content

Table 1 Overall statistics for EOC patients, patients with benign or low malignant potential (LMP) tumors, and healthy persons and patients with benign diseases as controls (A), clinicopathologic characteristics of FIGO I/II and FIGO III/IV patients (B) and diagnosis of patients with benign diseases (C)

From: A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer - a study of the OVCAD consortium

A)

Cohort 1

Typ

Number

FIGO

Age ± SD [years]

Range [years]

Controls

Healthy

90

n. a.

46.7 ± 16.8

19 - 83

Cystadenoma

6

n. a.

57.3 ± 8.5

45 - 66

LMP

8

n. a.

60.0 ± 18.6

32 - 92

Malignant disease

Ovarian cancer

19

FIGO I-II

55.5 ± 16.7

15 - 85

220

FIGO III-IV

58.6 ± 11.8

18 - 83

Cohort 2

Controls

Healthy

30

n. a.

  

Benign gynecological diseases

35

n. a.

47.3 ± 13.2

25 - 74

Malignant disease (overlapping with cohort 1)

Ovarian Cancer

14

FIGO I-II

  

210

FIGO III-IV

  

B)

FIGO I-II patients

19

   

  Histology

    

   Serous

14

   

   Endometrioid

2

   

   Mucinous

1

   

   Undifferentiated

2

   

  FIGO

    

   Ia

2

   

   Ic

7

   

   IIa

4

   

   IIb

2

   

   IIc

4

   

  Grade (1 missing)

    

   1

4

   

   2

6

   

   3

8

   

FIGO III-IV patients

220

   

  Histology (1 missing)

    

   Serous

194

   

   Endometrioid

4

   

   Mucinous

3

   

   Undifferentiated

6

   

   Mixed epithelial

12

   

  FIGO (3 missing)

    

   IIIa

4

   

   IIIb

7

   

   IIIc

166

   

   IV

40

   

  Grade (4 missing)

    

   1

8

   

   2

51

   

   3

157

   

C)

Benign diseases

35

   

Cystadenoma (mucinous)

9

   

Endometriosis

5

   

Ovarian fibroma

2

   

Uterine myoma

9

   

Miscellaneous (two with inflammatory conditions)

10